
What happens during a TGA inspection?
What Happens During a TGA Inspection?
A Therapeutic Goods Administration (TGA) inspection is an important assessment of whether a regulated manufacturing operation complies with applicable Good Manufacturing Practice (GMP) requirements. For therapeutic goods manufacturers, it provides an opportunity for the regulator to examine how quality systems operate in practice, how manufacturing activities are controlled and whether the organisation can consistently demonstrate that its products meet the required quality standards.
An inspection involves considerably more than reviewing standard operating procedures (SOPs) and checking whether documents have been approved. Inspectors assess the relationship between documented processes and actual working practices. They may examine manufacturing records, observe operations, interview personnel, review laboratory data and investigate how the organisation manages deviations, changes and quality risks.
For companies preparing for their first inspection, uncertainty about the process can create unnecessary concern. Understanding what inspectors generally examine, how findings are communicated and what happens after the inspection makes preparation more manageable.
The most effective approach is to maintain an inspection-ready quality system as part of normal operations. Documentation, training, equipment controls and quality oversight should be embedded in daily activities rather than assembled immediately before an inspector arrives.
Why Does the TGA Conduct GMP Inspections?
The TGA regulates therapeutic goods in Australia, including medicines and certain other therapeutic products. Its responsibilities include assessing compliance with applicable regulatory requirements and overseeing manufacturing activities within its regulatory remit.
GMP requirements are intended to ensure that products are consistently manufactured and controlled according to appropriate quality standards. They address the systems, facilities, personnel and processes involved in manufacturing and quality control.
An inspection allows the TGA to assess whether a manufacturer has established and maintains suitable controls. This includes examining whether the quality system is effective, whether manufacturing processes are appropriately managed and whether records provide reliable evidence of what has occurred.
Inspections may form part of regulatory assessment, ongoing compliance oversight or follow-up activity. Their scope and focus depend on the manufacturer, the products and activities involved, the regulatory circumstances and any relevant compliance history.
For overseas manufacturing sites supplying the Australian market, GMP evidence and overseas manufacturing arrangements may also be relevant. The applicable pathway depends on the circumstances and the regulatory requirements for the products concerned.
What Happens Before the Inspection?
Inspection preparation begins before the inspectors arrive. Depending on the circumstances, the TGA may communicate with the manufacturer or its relevant representatives to arrange inspection details and establish the proposed scope.
The organisation may be asked to provide information about its manufacturing activities, products, facilities, quality systems and relevant personnel. The information required will depend on the purpose and scope of the inspection.
Internally, the quality team should coordinate preparation across the departments likely to be involved. Manufacturing, quality assurance, quality control, engineering, validation, warehousing and management may all need to contribute.
A useful starting point is to review the current state of the quality system and identify any outstanding issues. This includes checking that controlled procedures are current, training records are complete, equipment documentation is available and quality events have been appropriately investigated.
The organisation should also consider whether previous audit findings, deviations or CAPAs remain unresolved. Outstanding actions should have documented assessments, assigned responsibilities and appropriate timelines.
Preparation should not involve creating records retrospectively or changing historical documentation to make the organisation appear compliant. Records must accurately represent what occurred. Where gaps are identified, they should be assessed and managed transparently through the appropriate quality processes.
The Opening Meeting
A GMP inspection commonly begins with an opening meeting involving the inspectors and relevant representatives of the organisation.
The meeting establishes the purpose, scope and practical arrangements for the inspection. Inspectors may explain the areas they intend to examine, identify the personnel they need to speak with and discuss how information and records will be made available.
The organisation should identify its key contacts, including the person responsible for coordinating inspection activities and the relevant quality representative.
It is useful to establish practical arrangements for document requests, access to facilities, interviews and communication between departments. Personnel should understand who is authorised to coordinate responses and how requested information will be retrieved.
The opening meeting is also an opportunity to clarify the inspection scope. If the organisation does not understand a request or the area being examined, it should seek clarification rather than make assumptions.
Facility and Manufacturing Area Inspection
Inspectors may conduct a walkthrough of relevant facility areas to assess whether the premises, equipment and operating conditions are suitable for the activities performed.
The areas examined depend on the facility and inspection scope. They may include manufacturing rooms, packaging areas, laboratories, warehouses, sampling areas, equipment rooms and other supporting spaces.
During a walkthrough, inspectors may consider:
Facility layout and material flow.
Personnel movement and access controls.
Cleaning and housekeeping practices.
Equipment identification and status.
Environmental conditions and monitoring, where relevant.
Storage conditions for materials and products.
Segregation and identification of materials.
Waste handling and contamination controls.
Maintenance of premises and equipment.
Inspectors may observe personnel carrying out routine activities and compare actual practices with approved procedures. For example, they may examine whether equipment status is clearly identified, whether materials are appropriately labelled and whether personnel follow the required gowning or hygiene practices.
The condition of the facility is important, but appearance alone does not establish GMP compliance. Inspectors are interested in whether the organisation has effective systems to maintain the premises and control the activities performed within them.
Review of the Pharmaceutical Quality System
The Pharmaceutical Quality System (PQS) is likely to receive significant attention during a GMP inspection.
Inspectors examine whether the organisation has established appropriate quality governance and whether the system is operating effectively. This includes reviewing the responsibilities of management and the quality function, as well as the processes used to identify, investigate and control quality issues.
Typical areas of review include:
Document control: Inspectors may check whether procedures are approved, current, accessible to relevant personnel and protected against unintended use of obsolete versions.
Deviation management: They may examine how unexpected events are reported, investigated, assessed for potential product impact and documented.
Corrective and preventive action: CAPAs may be reviewed to determine whether identified causes have been addressed and whether the effectiveness of actions has been evaluated.
Change control: Inspectors may assess whether changes to equipment, processes, materials, procedures and facilities are evaluated and approved appropriately.
Quality risk management: They may examine whether quality risks are identified, assessed and managed using scientifically justified approaches.
Supplier oversight: The organisation may need to demonstrate that suppliers and contract service providers are assessed and monitored according to the risks associated with their activities.
Management review: Evidence may be examined to determine whether management receives appropriate quality information and provides oversight of system performance.
Having a procedure for each activity is not enough. Inspectors will be interested in whether the procedures are followed and whether the resulting records demonstrate effective control.
Manufacturing and Batch Record Review
Manufacturing documentation provides evidence that products have been produced according to approved instructions and within established controls.
Inspectors may review batch manufacturing and packaging records, material dispensing records, equipment logs, in-process checks and other documentation relevant to the products within scope.
They may trace a particular batch through the manufacturing process, examining how materials were received, identified, approved, issued and used. They may also check whether processing steps were completed, recorded and reviewed appropriately.
Particular attention may be given to unexplained discrepancies, incomplete entries, undocumented changes, missing signatures and inconsistencies between records.
If a process step was not performed as expected, the organisation should be able to demonstrate how the event was documented and assessed. Records should not simply show that a batch was completed; they should provide reliable evidence of how it was manufactured and controlled.
Inspectors may also examine how the quality unit performs its responsibilities, including the review of manufacturing documentation and decisions relating to product disposition.
Laboratory and Quality Control Activities
Quality control laboratories are another important area of GMP oversight because analytical results contribute to decisions about materials, in-process controls and finished product quality.
Inspectors may review analytical methods, laboratory procedures, instrument records, raw data, calculations and analytical reports.
They may examine whether methods are suitable for their intended purpose and whether validation or verification activities have been appropriately documented. Equipment calibration, maintenance and performance checks may also be assessed.
Sample management is particularly important. The laboratory should be able to demonstrate how samples are received, identified, stored, tested and reported, with traceability maintained throughout the process.
Out-of-specification results and other unexpected laboratory findings may receive close attention. Inspectors may examine whether investigations are scientifically sound, whether potential causes have been considered and whether conclusions are supported by evidence.
Data integrity is central to laboratory compliance. Original data, electronic records, audit trails and associated documentation should provide a complete and reliable account of analytical activities. Where electronic systems are used, access controls and other safeguards should be appropriate to their intended use and applicable requirements.
Personnel Interviews and Training Records
Inspectors may speak with personnel at different levels of the organisation to understand how procedures are implemented.
Questions may relate to an individual's responsibilities, the procedures they follow, how they report problems and what actions they take when an unexpected event occurs.
Personnel should be familiar with the activities they perform and understand the relevant quality requirements. They are not expected to memorise every procedure, but they should know where to find current instructions and how to obtain assistance when necessary.
Training records may be reviewed to confirm that personnel have received appropriate training before performing assigned tasks. Depending on the activity, practical competency assessment or supervised qualification may also be relevant.
A difference between documented training and actual competency can indicate weaknesses in the training system. Organisations should therefore ensure that training is meaningful and relevant to the work being performed.
How Inspectors Identify and Communicate Findings
During an inspection, inspectors may identify observations or deficiencies that require clarification, further investigation or formal reporting.
A finding may relate to a specific record, a failure to follow a procedure, an inadequate control or a broader weakness in the quality system. The significance depends on the nature of the issue and its potential impact on product quality, patient safety and GMP compliance.
Inspectors may ask additional questions, request supporting records or examine other examples to determine whether an issue is isolated or indicative of a wider problem.
At the conclusion of the inspection, findings are generally discussed with the organisation's representatives. The closing meeting provides an opportunity to communicate the inspectors' observations and explain the next steps in the reporting process.
The organisation should listen carefully, clarify points it does not understand and take accurate notes. It should avoid making unsupported commitments or attempting to dismiss an issue without considering the evidence.
The formal inspection outcome and any required response will be communicated through the applicable TGA process.
What Happens After the Inspection?
Following the inspection, the organisation may need to respond to identified deficiencies and provide evidence of corrective action.
The response should address each finding individually. It should explain the issue, assess its potential impact, identify the underlying cause and describe the corrective and preventive actions proposed or completed.
An effective response goes beyond stating that a procedure has been updated or personnel have been retrained. It should demonstrate that the organisation has understood why the problem occurred and has introduced appropriate measures to prevent recurrence.
For significant findings, the organisation may need to assess whether other products, batches, processes or records could have been affected. The extent of this assessment should be supported by documented evidence and a scientifically justified rationale.
CAPA actions should have assigned owners, defined completion expectations and appropriate effectiveness checks. Evidence of implementation should be retained.
Depending on the nature of the findings and regulatory circumstances, the TGA may require further information, additional follow-up or other regulatory action. The outcome will depend on the inspection findings and the applicable regulatory framework.
Common Reasons Organisations Struggle During TGA Inspections
Many inspection difficulties arise because documented quality systems do not adequately reflect actual operational practices.
For example, a procedure may describe a review or approval process that personnel do not consistently follow. Equipment records may be incomplete, training may not reflect current procedures, or investigations may identify immediate causes without addressing underlying weaknesses.
Other common areas of difficulty include:
Incomplete or inconsistent batch records.
Uncontrolled documents or obsolete procedures in use.
Inadequate deviation investigations.
CAPAs without meaningful effectiveness checks.
Poorly justified changes to validated processes.
Gaps in equipment qualification or maintenance records.
Inadequate supplier oversight.
Incomplete laboratory data or audit trail review.
Insufficient evidence of personnel competency.
Limited management oversight of quality performance.
These issues are not necessarily resolved by increasing the number of procedures. The organisation needs to understand where its controls are failing and improve the systems responsible for maintaining compliance.
How to Maintain Ongoing Inspection Readiness
Inspection readiness should be part of routine quality management.
Internal audits can assess whether procedures are being followed and whether records demonstrate compliance. Management review can identify recurring problems, resource constraints and areas requiring improvement.
Quality metrics may help identify trends in deviations, CAPAs, change controls, complaints, audit findings and other relevant activities. Metrics should be interpreted carefully, as an increase in reported deviations, for example, may reflect improved reporting rather than deteriorating performance.
Personnel should receive ongoing training, and procedures should be reviewed when processes, equipment, facilities or regulatory expectations change.
Organisations should also ensure that records are readily retrievable. A document management system that is difficult to navigate can make it unnecessarily challenging to respond to inspection requests, even when the required information exists.
A consistent approach to documentation, recordkeeping and quality oversight makes inspection preparation a continuation of normal operations rather than a separate project.
How QSN Can Help Prepare Your Organisation
Preparing for a TGA inspection requires a clear understanding of applicable GMP requirements and the practical ability to demonstrate that the quality system is effective.
QSN Academy supports therapeutic goods manufacturers, testing laboratories and biotechnology companies with GxP and regulatory compliance training activities. This can include reviewing existing quality systems, identifying compliance gaps, developing and revising SOPs, strengthening document management and improving processes for deviations, CAPA and change control.
Where technical documentation is required, collaboration with internal subject matter experts helps ensure that procedures and supporting records accurately reflect operational activities.
A structured readiness assessment can help identify areas requiring attention before an inspection and establish priorities for improvement. The focus is on developing practical systems that personnel can understand, maintain and apply consistently.
Conclusion
A TGA inspection examines how effectively an organisation controls its regulated manufacturing activities and demonstrates compliance with applicable GMP requirements.
The process may involve facility walkthroughs, document reviews, manufacturing and laboratory assessments, personnel interviews and detailed examination of the Pharmaceutical Quality System. Inspectors look beyond approved procedures to determine whether controls are implemented consistently and supported by reliable evidence.
Following the inspection, any identified deficiencies need to be assessed and addressed through appropriate corrective and preventive actions. The organisation must demonstrate that its responses are effective and that quality risks have been properly considered.
The strongest preparation is achieved through an effective quality system that operates every day. Clear procedures, competent personnel, reliable records and active management oversight provide the foundation for maintaining compliance and approaching a TGA inspection with confidence.
Clarify the TGA inspection sequenceAdd a practical inspection-day checklist
